BHV-1440 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving BHV-1440 Growth

• Novel TRAP™ Platform Targets the Root Cause of Graves' Disease

BHV-1440 is designed to selectively degrade pathogenic TSHR autoantibodies, rather than broadly suppressing the immune system. Unlike antithyroid drugs, radioactive iodine, or thyroidectomy, which primarily control thyroid hormone production or remove thyroid tissue, BHV-1440 aims to eliminate the disease-causing autoantibodies responsible for both Graves' disease and TED. Biohaven positions BHV-1440 as a next-generation immune therapy built on its proprietary TRAP extracellular protein degradation platform, offering the potential for disease modification while preserving normal immune function.

• Validation of the TRAP™/MoDE™ Platform by Clinical Success of BHV-1300

Although BHV-1440 has not yet entered clinical trials, its development is substantially de-risked by encouraging human data generated with BHV-1300, Biohaven's first clinical extracellular degrader for Graves' disease. In clinical studies, BHV-1300 produced greater than 80% reductions in pathogenic TSHR-IgG1 autoantibodies over 12 weeks, with normalization of thyroid hormone levels occurring within weeks in treated patients. These data provide strong proof-of-concept that selective degradation of disease-driving antibodies can translate into meaningful clinical benefit, increasing confidence in follow-on TRAP programs such as BHV-1440.

• Large Unmet Need in Graves' Disease and Thyroid Eye Disease

Graves' disease affects approximately 1% of the global population, and a substantial proportion of patients develop TED. Current therapies often fail to address the underlying autoimmune mechanism, resulting in persistent symptoms, disease relapse, or irreversible thyroid destruction. Biohaven notes that no new FDA-approved therapy targeting the underlying cause of Graves' disease had been introduced for more than 70 years, highlighting the opportunity for disease-modifying biologics such as BHV-1440. The ability to potentially treat both Graves' disease and TED further expands its commercial opportunity.

• Highly Selective Precision Immunology Approach

Unlike FcRn inhibitors or broad B-cell-depleting therapies that reduce total immunoglobulin levels, BHV-1440 is engineered to selectively remove TSHR autoantibodies while sparing protective antibodies. This precision approach could reduce infection risk and improve long-term tolerability, providing a meaningful competitive advantage if demonstrated clinically. Biohaven has emphasized this selectivity as a defining feature of its TRAP platform and a key differentiator from conventional immunosuppressive strategies.

• Strong Pipeline Synergies and Platform Expansion

BHV-1440 is part of Biohaven's expanding portfolio of extracellular protein degraders targeting distinct pathogenic antibodies across autoimmune diseases, including programs for membranous nephropathy (BHV-1420), pemphigus vulgaris (BHV-1450), type 1 diabetes (BHV-6500), and other immune-mediated disorders. Successful clinical validation of the platform in one indication is expected to facilitate development across the broader pipeline, creating manufacturing, regulatory, and commercial synergies that could accelerate BHV-1440's development.

BHV-1440 Recent Developments

In March 2026, first dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses. BHV-1400 previously achieved rapid lowering of Gd-IgA1 with a mean reduction of >60% within hours and maximum reduction exceeding 80% in a study conducted in healthy volunteers. A pivotal study is set to initiate in the first quarter of 2026.

“BHV-1440 Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of BHV-1440 for potential indication like Graves ophthalmopathy and Graves’ disease in the 7MM. A detailed picture of BHV-1440’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the BHV-1440 for potential indications. The BHV-1440 market report provides insights about BHV-1440’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current BHV-1440 performance, future market assessments inclusive of the BHV-1440 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of BHV-1440 sales forecasts, along with factors driving its market.

BHV-1440 Drug Summary

BHV-1440 is an investigational targeted extracellular protein degrader (TRAP degrader) being developed by Biohaven for the treatment of Graves' disease (GD) and thyroid eye disease (TED). The therapy is designed to selectively recognize and degrade pathogenic thyroid-stimulating hormone receptor (TSHR) autoantibodies, which are the primary drivers of both hyperthyroidism and the extrathyroidal manifestations of Graves' disease. Unlike conventional immunosuppressive therapies that broadly suppress immune function, BHV-1440 employs Biohaven's TRAP degrader platform to specifically eliminate disease-causing TSHR autoantibodies while sparing the remainder of the immune system, offering the potential for a precision, disease-modifying approach. By removing these pathogenic autoantibodies, BHV-1440 aims to interrupt the autoimmune cascade responsible for thyroid dysfunction, orbital inflammation, and tissue remodeling in TED. As of 2026, BHV-1440 remains in preclinical development as part of Biohaven's next-generation degrader portfolio, with no human clinical trials initiated or regulatory approvals granted. The report provides BHV-1440’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the BHV-1440 Market Report

The report provides insights into:

• A comprehensive product overview including the BHV-1440 MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy and Graves’ disease.
• Elaborated details on BHV-1440 regulatory milestones and other development activities have been provided in BHV-1440 market report.
• The report also highlights BHV-1440‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The BHV-1440 market report also covers the patents information, generic entry and impact on cost cut.
• The BHV-1440 market report contains current and forecasted BHV-1440 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The BHV-1440 market report also features the SWOT analysis with analyst views for BHV-1440 in potential indications.

Methodology

The BHV-1440 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BHV-1440 Analytical Perspective

• In-depth BHV-1440 Market Assessment

This BHV-1440 sales market forecast report provides a detailed market assessment of BHV-1440 for potential indication like Graves ophthalmopathy and Graves’ disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted BHV-1440 sales data uptil 2034.

• BHV-1440 Clinical Assessment

The BHV-1440 market report provides the clinical trials information of BHV-1440 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

BHV-1440 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

BHV-1440 Market Potential & Revenue Forecast

• Projected market size for the BHV-1440 and its key indications
• Estimated BHV-1440 sales potential (BHV-1440 peak sales forecasts)
• BHV-1440 Pricing strategies and reimbursement landscape

BHV-1440 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• BHV-1440 Market positioning compared to existing treatments
• BHV-1440 Strengths & weaknesses relative to competitors

BHV-1440 Regulatory & Commercial Milestones

• BHV-1440 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

BHV-1440 Clinical Differentiation

• BHV-1440 Efficacy & safety advantages over existing drugs
• BHV-1440 Unique selling points

BHV-1440 Market Report Highlights

• In the coming years, the BHV-1440 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The BHV-1440 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BHV-1440’s dominance.
• Other emerging products for Graves ophthalmopathy and Graves’ disease are expected to give tough market competition to BHV-1440 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BHV-1440 in potential indications.
• Analyse BHV-1440 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted BHV-1440 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of BHV-1440 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of BHV-1440? How strong is BHV-1440’s clinical and commercial performance?
• What is BHV-1440’s clinical trial status in each individual indications such as Graves ophthalmopathy and Graves’ disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BHV-1440 Manufacturers?
• What are the key designations that have been granted to BHV-1440 for potential indications? How are they going to impact BHV-1440’s penetration in various geographies?
• What is the current and forecasted BHV-1440 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of BHV-1440 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to BHV-1440 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is BHV-1440? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.